Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review)
- Authors:
- Ziliang Jin
- Weihua Jiang
- Liwei Wang
-
Affiliations: Department of Oncology, Shanghai Key Laboratory of Pancreatic Diseases, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, P.R. China - Published online on: February 12, 2015 https://doi.org/10.3892/ol.2015.2959
- Pages: 1502-1508
This article is mentioned in:
Abstract
|
Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hu B, El Hajj N, Sittler S, et al: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 3:251–261. 2012.PubMed/NCBI | |
|
Nitti D, Mocellin S, Marchet A, Pilati P and Lise M: Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surg Oncol Clin N Am. 17:467–483. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Resende C, Ristimäki A and Machado JC: Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter. 15:34–39. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pectasides D, Mylonakis A, Kostopoulou M, et al: CEA, CA 19–9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol. 20:348–353. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wu WK, Lee CW, Cho CH, et al: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ye T, Chen Y and Fang J: DNA methylation biomarkers in serum for gastric cancer screening. Mini Rev Med Chem. 10:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Huang CM, Zheng CH, et al: Prognostic value of tumor size in patients with remnant gastric cancer: Is the seventh UICC stage sufficient for predicting prognosis? PloS One. 9:e1157762014. View Article : Google Scholar : PubMed/NCBI | |
|
Gold P and Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 122:467–481. 1965. View Article : Google Scholar : PubMed/NCBI | |
|
Tatsuta M, Itoh T, Okuda S, et al: Carcinoembryonic antigen in gastric juice as an aid in diagnosis of early gastric cancer. Cancer. 46:2686–2692. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Szymendera JJ: Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125. Tumour Biol. 7:333–342. 1986.PubMed/NCBI | |
|
Tsukamoto Y, Nakada C, Noguchi T, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oh HK, Tan AL, Das K, et al: Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 17:2657–2667. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Katada T, Ishiguro H, Kuwabara Y, et al: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 34:537–542. 2009.PubMed/NCBI | |
|
Ueda T, Volinia S, Okumura H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar | |
|
Song JH and Meltzer SJ: MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 143:35–47.e2. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Li C, Nie H, et al: Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 586:2382–2388. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yamanaka S, Olaru AV, An F, et al: MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis. 44:589–596. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Fan R, Wang L, et al: Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 34:963–971. 2013. View Article : Google Scholar | |
|
Crone SG, Jacobsen A, Federspiel B, et al: microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer. 11:712012. View Article : Google Scholar | |
|
Sacconi A, Biagioni F, Canu V, et al: miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 3:e4232012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Zhao F, Wang Z, et al: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : | |
|
Cai H, Yuan Y, Hao YF, et al: Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 30:4522013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Cui L, Ye G, et al: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 33:2349–2355. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Luo L, Wu Y, et al: Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol. 30:3652013. View Article : Google Scholar : PubMed/NCBI | |
|
Compare D, Rocco A, Liguori E, et al: Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol. 64:677–682. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oishi Y, Watanabe Y, Yoshida Y, et al: Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol. 33:383–393. 2012. View Article : Google Scholar | |
|
Hudler P: Genetic aspects of gastric cancer instability. ScientificWorldJournal. 2012:7619092012. View Article : Google Scholar : PubMed/NCBI | |
|
Ling ZQ, Tanaka A, Li P, et al: Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett. 297:244–251. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ohue M, Tomita N, Monden T, et al: Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer. Int J Cancer. 68:203–206. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Iacopetta BJ, Soong R, House AK and Hamelin R: Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol. 187:428–432. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Fleisher AS, Esteller M, Wang S, et al: Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59:1090–1095. 1999.PubMed/NCBI | |
|
Choi SW, Choi JR, Chung YJ, et al: Prognostic implications of microsatellite genotypes in gastric carcinoma. Int J Cancer. 89:378–383. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Wirtz HC, Müller W, Noguchi T, et al: Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res. 4:1749–1754. 1998.PubMed/NCBI | |
|
dos Santos NR, Seruca R, Constância M, et al: Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 110:38–44. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Yasui W, Sumiyoshi H, Hata J, et al: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 48:137–141. 1988.PubMed/NCBI | |
|
Sakai K, Mori S, Kawamoto T, et al: Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 77:1047–1052. 1986.PubMed/NCBI | |
|
García I, Vizoso F, Martín A, et al: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 10:234–241. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Terashima M, Kitada K, Ochiai A, et al; ACTS-GC Group. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Li N, Jiang W, et al: Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 10:2742012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Jeon TJ, Bae BN, et al: The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma. APMIS. 121:95–104. 2013. View Article : Google Scholar | |
|
Ye YW, Zhang X, Zhou Y, et al: The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients. J Surg Oncol. 106:872–879. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Amemiya H, Kono K, Itakura J, et al: c-Met expression in gastric cancer with liver metastasis. Oncology. 63:286–296. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Graziano F, Galluccio N, Lorenzini P, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 29:4789–4795. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Warnecke-Eberz U, Bollschweiler E, Drebber U, et al: Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 29:4451–4455. 2009.PubMed/NCBI | |
|
Ishigami S, Natsugoe S, Okumura H, et al: Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol. 14:3154–3158. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DK, Oh SY, Kwon HC, et al: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 9:1552009. View Article : Google Scholar : PubMed/NCBI | |
|
Liao WC, Lin JT, Wu CY, et al: Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 14:428–434. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nagashima N, Nakayama Y, Inoue Y, et al: Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancer. Anticancer Res. 28:1277–1283. 2008.PubMed/NCBI | |
|
Ashizawa T, Okada R, Suzuki Y, et al: Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 8:124–131. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Graziano F, Ruzzo A, Santini D, et al: Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. J Clin Oncol. 23:2339–2345. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Macrì A, Versaci A, Loddo S, et al: Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers. 11:184–193. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Necula LG, Chivu-Economescu M, Stanciulescu EL, et al: IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis. 21:23–29. 2012.PubMed/NCBI | |
|
Lin MT, Lin BR, Chang CC, et al: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer. 120:2600–2608. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Cho YS, Lee JY, et al: The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer. Ann Surg. 249:933–941. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al: The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol. 91:243–252. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tenderenda M: A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res. 24:405–414. 2005.PubMed/NCBI | |
|
Nitti D, Belluco C, Mammano E, et al: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol. 81:167–175; discussion 175–166. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xiangming C, Natsugoe S, Takao S, et al: The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer. 89:1214–1219. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sgambato A, Migaldi M, Leocata P, et al: Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer. 89:2247–2257. 2000. View Article : Google Scholar | |
|
Ichiyoshi Y, Oiwa H, Tomisaki S, et al: Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology. 44:546–553. 1997.PubMed/NCBI | |
|
Gonçalves AR, Carneiro AJ, Martins I, et al: Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res. 17:349–355. 2011. View Article : Google Scholar | |
|
Feakins RM, Nickols CD, Bidd H and Walton SJ: Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol. 34:1276–1282. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Aurello P, Bellagamba R, Rossi Del Monte S, et al: Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 75:1183–1188. 2009.PubMed/NCBI | |
|
Koshida Y, Saegusa M and Okayasu I: Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer. 75:367–373. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Inada T, Kikuyama S, Ichikawa A, et al: Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res. 18:2003–2010. 1998.PubMed/NCBI | |
|
Aizawa K, Ueki K, Suzuki S, et al: Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol. 14:85–91. 1999. | |
|
Osaki M, Kase S, Kodani I, et al: Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer. 4:198–205. 2001. View Article : Google Scholar | |
|
Nagashima H, Mori M, Sadanaga N, et al: Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol. 18:1157–1162. 2001.PubMed/NCBI | |
|
Liu X, Cai H, Huang H, et al: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One. 6:e296702011. View Article : Google Scholar | |
|
Lee HK, Lee HS, Yang HK, et al: Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 18:518–525. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Lee HE, Lee HS, et al: Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Komatsu S, Ichikawa D, Tsujiura M, et al: Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33:271–276. 2013. | |
|
Cui L, Zhang X, Ye G, et al: Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 119:1618–1626. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JL, Gao W, Kang QM, et al: Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PLoS One. 8:e719302013. View Article : Google Scholar : PubMed/NCBI | |
|
Okada E, Murai Y, Matsui K, et al: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 163:109–116. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Song KY, Jung CK, Park WS and Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol. 39:290–296. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BH, Hong SW, Kim A, et al: Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107:505–510. 2013. View Article : Google Scholar | |
|
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med. 10:1862012. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AS, Li MS, Kang W, et al: Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology. 144:122–133.e9. 2013. View Article : Google Scholar | |
|
Yu QM, Wang XB, Luo J, et al: CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol. 106:765–771. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Park SJ, Jang HR, Kim M, et al: Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis. 33:1494–1501. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Negrini M, Miotto E, Sabbioni S, et al: MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer. Eur J Cancer Prev. 21:442–448. 2012. View Article : Google Scholar | |
|
Hu SL, Kong XY, Cheng ZD, et al: Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori. 96:726–733. 2010. | |
|
Huang FY, Chan AO, Rashid A, et al: Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1β activation of nitric oxide production in gastric cancer cells. Cancer. 118:4969–4980. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wani M, Afroze D, Makhdoomi M, et al: Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pac J Cancer Prev. 13:4177–4181. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hibi K, Sakata M, Yokomizi K, et al: Methylation of the WNT5A gene is frequently detected in early gastric carcinoma. Hepatogastroenterology. 59:2661–2663. 2012.PubMed/NCBI | |
|
Guo W, Dong Z, Guo Y, et al: Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clin Exp Metastasis. 30:265–275. 2013. View Article : Google Scholar | |
|
Wang XH, Zhang LH, Zhong XY, et al: S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol. 177:586–597. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sugita H, Iida S, Inokuchi M, et al: Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep. 25:513–518. 2011. View Article : Google Scholar | |
|
Li X, Cheung KF, Ma X, et al: Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene. 31:3419–3430. 2012. View Article : Google Scholar | |
|
Zhan Z, Wu J, Zhang JF, et al: CDH1 gene polymorphisms, plasma CDH1 levels and risk of gastric cancer in a Chinese population. Mol Biol Rep. 39:8107–8113. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan LJ, Jin TB, Yin JK, et al: Polymorphisms of tumor-related genes IL-10, PSCA, MTRR and NOC3 L are associated with the risk of gastric cancer in the Chinese Han population. Cancer Epidemiol. 36:e366–e372. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xue H, Lu Y, Lin B, et al: The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One. 7:e434312012. View Article : Google Scholar : PubMed/NCBI | |
|
Tian J, Pan F, Li J, et al: Association between the FAS/FASL polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 13:945–951. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ozen A, Kocak Z, Sipahi T, et al: The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol. 30:3572013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu R, Gao X, Chen Y, et al: Association of an NFKB1 intron SNP (rs4648068) with gastric cancer patients in the Han Chinese population. BMC Gastroenterol. 12:872012. View Article : Google Scholar : PubMed/NCBI | |
|
He J, Xu Y, Qiu LX, et al: Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. PLoS One. 7:e493082012. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Lee SW, Yoon JH, et al: Association of SOD1 and SOD2 single nucleotide polymorphisms with susceptibility to gastric cancer in a Korean population. APMIS. 121:246–256. 2013. View Article : Google Scholar | |
|
Han F, Wang X, Wang X, Luo Y and Li W: Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Mol Biol Rep. 39:8335–8344. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang XP, Bai ZB, Chen BA, et al: Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Chin Med J (Engl). 125:741–746. 2012. | |
|
Oh SY, Kwon HC, Kim SH, et al: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 13:432013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Wei J, Zou Z, et al: Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet. 15:1049–1053. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Li QF, Yao RY, Liu KW, et al: Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci. 25:846–852. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JG, Sohn SK, Chae YS, et al: TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol. 64:355–360. 2009. View Article : Google Scholar | |
|
Shirai O, Ohmiya N, Taguchi A, et al: P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology. 57:1595–1601. 2010. | |
|
Wang S, Chen L, Zhao Q, et al: Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy. Cancer Chemother Pharmacol. 71:1073–1082. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
García-González MA, Nicolás-Pérez D, Lanas A, et al: Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma. PLoS One. 7:e461792012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Song B, Wang JL, et al: Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol. 17:1362–1367. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tahara T, Shibata T, Nakamura M, et al: Effect of IL-1β and TNF-α polymorphisms on the prognosis and survival of gastric cancer patients. Clin Exp Med. 11:211–217. 2011. View Article : Google Scholar : PubMed/NCBI |
